Clinical Trials Logo

Filter by:
NCT ID: NCT02497222 Withdrawn - Asthma Clinical Trials

Pilot Study of RNS60 in Allergen-induced Bronchoconstriction

Start date: n/a
Phase: Phase 2
Study type: Interventional

This study evaluates the use of RNS60 in the treatment of asthma examining regional improvements in inflammation using PET imaging. All subjects will be treated with both RNS60 and placebo in a crossover design.

NCT ID: NCT02496975 Withdrawn - Clinical trials for Traumatic Brain Injury

Traumatic Brain Injury and Effects of Acute Cyclosporine A

Start date: August 7, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a prospective, randomized, placebo-controlled study about Cyclosporine A (CSP) and traumatic brain injury (TBI). Cyclosporine A is a drug already marketed and available for other diseases, but is not approved by the Food and Drug Administration for treatment of traumatic brain injury. The effect of Cyclosporine A on chemicals produced following brain injury is being determined using doses no larger than those used for patients having organ transplant. It is also being given for a much shorter time period (3 days). It is not know if side effects seen in patients taking cyclosporine A will occur when it is given for only 3 days. It is not known if patients with brain injury that are treated with cyclosporine A will have side effects like those seen in organ transplant patients.

NCT ID: NCT02495636 Withdrawn - Clinical trials for Non-Small Cell Lung Cancer

Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer

Start date: July 2015
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to look at effects, good or bad, of combining two investigational anti-cancer drugs called MPDL3280A and CDX-1401. CDX-1401 is given in combination with a third agent, poly-ICLC, which is another investigational drug that is believed to work together with CDX-1401. All investigational drugs, MPDL3280A and CDX-1401 in conjunction with poly-ICLC, have been evaluated separately in prior studies; however, this is the first study assessing the combination therapy.

NCT ID: NCT02493374 Withdrawn - Type 2 Diabetes Clinical Trials

Mitigation of Type 2 Diabetes by Partial Ileal Bypass

Start date: May 2016
Phase:
Study type: Observational

This is a study of people with type 2 diabetes and high cholesterol between age 18 and 65. This study is trying to figure out if a partial bypass of the small intestine can reverse type 2 diabetes for people who require cholesterol lowering and who cannot tolerate the statin drugs.

NCT ID: NCT02492360 Withdrawn - Clinical trials for Peripheral Nervous System Diseases

Establishing of Neuronal-like Cells From Patients With Cisplatin-Induced Peripheral Neuropathy

Start date: December 2017
Phase: N/A
Study type: Observational

This study targets patients with cisplatin-induced peripheral neuropathy and will allow us to: a) study peripheral neuropathy in diverse human sensory neurons in ways that were not possible previously; b) gain insight on druggable targets to treat or prevent this devastating side effect of chemotherapy; c) provide a human cellular model that can be used for screening of drugs to determine if they are neurotoxic. The combination of patient information and in vitro measurements provides a highly relevant and clinically useful model for studies aimed to impact treatment selection for the individual cancer patient.

NCT ID: NCT02492048 Withdrawn - Wounds and Injuries Clinical Trials

Effectiveness of CelluTome Epidermal Harvesting System in Autologous Skin Grafting of Chronic Wound Patients

Start date: December 16, 2014
Phase: N/A
Study type: Interventional

This is multi-center prospective, longitudinal case series with comparison to historical controls.

NCT ID: NCT02488889 Withdrawn - Cigarette Smoking Clinical Trials

Effects of Varenicline in Heavy Drinking Smokers

VAR
Start date: August 2015
Phase: Phase 4
Study type: Interventional

This laboratory study will examine if varenicline can reduce alcohol-induced smoking lapse in heavy drinking smokers.

NCT ID: NCT02487953 Withdrawn - Nicotine Dependence Clinical Trials

Electronic Nicotine Delivery Systems as a Smoking Cessation Treatment

ENDS-P50
Start date: July 2018
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to determine whether combining electronic nicotine delivery systems (ENDS) with nicotine patch treatment will augment abstinence rates compared to either treatment alone.

NCT ID: NCT02487459 Withdrawn - Clinical trials for Hematologic Malignancies

Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies

Start date: July 2016
Phase: Phase 1
Study type: Interventional

This is an open-label, non-randomized study to evaluate the safety of two planned infusions of BPX-501 T cells after partially mismatched, related (haploidentical) HSCT in adults with hematologic malignancies.

NCT ID: NCT02485366 Withdrawn - Clinical trials for Heart Defects, Congenital

Rejuvenated, Washed Packed Red Blood Cells in Pediatric Cardiac Surgery

Start date: June 2020
Phase: Phase 4
Study type: Interventional

Blood transfusion is nearly always needed during open heart surgery in children less than 15 kg (35 pounds). The purpose of the red blood cells in the blood is to deliver oxygen to the organs and tissues of the body. Stored blood undergoes some changes that may make it less effective in achieving this goal. The purpose of this study is to see if restoring important energy molecules (ATP and 2,3,DPG) in stored red blood cells before they are transfused, with a rejuvenating solution (Rejuvesol), offers any advantages to children over standard blood transfusion. This is a Food and Drug Administration (FDA) approved process that is described by the American Association of Blood Banks for prolonging blood storage but not used for everyday transfusions. The investigators want to use this process to improve blood transfused to children undergoing heart surgery. Although Rejuvesol has been previously approved by the FDA, it is not routinely used to prepare standard blood transfusions to children undergoing surgery. Use of Rejuvesol in this study is considered investigational. This is a pilot study and data will be collected for future protocol development.